Skip to main content

Advertisement

SpringerLink
Log in

How effective is fluoxetine for the treatment of pain and constipation-predominant irritable bowel syndrome?

  • Practice Point
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gorard DA et al. (1994) Influence of antidepressants on whole gut orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 8: 159–166

    Article  CAS  Google Scholar 

  2. Chial HJ et al. (2003) Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 1: 211–218

    Article  CAS  Google Scholar 

  3. Coates MD et al. (2004) Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657–1664

    Article  CAS  Google Scholar 

  4. Creed F et al. (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124: 303–317

    Article  Google Scholar 

  5. Kuiken SD et al. (2003) The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastoenterol Hepatol 1: 219–228

    Article  CAS  Google Scholar 

  6. Weinrieb RM et al. (2005) Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf 4: 337–344

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine and the Director of the Motility Interest Group in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, MN, USA

    Nicholas J Talley

Authors
  1. Nicholas J Talley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas J Talley.

Ethics declarations

Competing interests

Nicholas J Talley is a consultant for AstraZeneca, Axcan, EBMed, Giaconda, Medscape, Solvay, Theravance, Yamanouchi, Boehringer-Ingelheim, and Chugai. He receives research support from Merck, Novartis, and Tap Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talley, N. How effective is fluoxetine for the treatment of pain and constipation-predominant irritable bowel syndrome?. Nat Rev Gastroenterol Hepatol 3, 196–197 (2006). https://doi.org/10.1038/ncpgasthep0444

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0444

  • Springer Nature Limited

Search

Navigation